Genentech, founded in 1976 by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer, is a biotechnology company focused on discovering and developing medicines for people with serious and life-threatening diseases. A member of the Roche Group, the company operates out of the United States and has committed $50 billion to U.S. manufacturing and research and development.
Over nearly 50 years, Genentech's work has spanned drug discovery, biopharmaceutical manufacturing, clinical research, and personalized medicine. Among its notable developments are the first personalized medicine for cancer and the first medicine approved for primary progressive multiple sclerosis. The company is also integrating AI into molecule discovery and maintains state-of-the-art manufacturing facilities as part of its research infrastructure.
Genentech's technical domains include:
- Biotechnology and biomedical research
- Drug discovery and biopharmaceutical manufacturing
- Personalized and precision medicine
- AI-assisted molecule discovery
- Clinical trials and clinical research
- Customer engagement strategies for healthcare
The company has stated commitments to reducing barriers to clinical trial participation, advancing inclusive research, and improving health outcomes across patient populations.